Tags

Type your tag names separated by a space and hit enter

Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients.
Med Mal Infect. 2020 Aug; 50(5):397-400.MM

Abstract

INTRODUCTION

No therapy has yet proven effective in COVID-19. Tocilizumab (TCZ) in patients with severe COVID-19 could be an effective treatment.

METHOD

We conducted a retrospective case-control study in the Nord Franche-Comté Hospital, France. We compared the outcome of patients treated with TCZ and patients without TCZ considering a combined primary endpoint: death and/or ICU admissions.

RESULTS

Patients with TCZ (n=20) had a higher Charlson comorbidity index (5.3 [±2.4] vs 3.4 [±2.6], P=0.014), presented with more severe forms (higher level of oxygen therapy at 13L/min vs 6L/min, P<0.001), and had poorer biological findings (severe lymphopenia: 676/mm3 vs 914/mm3, P=0.037 and higher CRP level: 158mg/L vs 105mg/L, P=0.017) than patients without TCZ (n=25). However, death and/or ICU admissions were higher in patients without TCZ than in the TCZ group (72% vs 25%, P=0.002).

CONCLUSION

Despite the small sample size and retrospective nature of the work, this result strongly suggests that TCZ may reduce the number of ICU admissions and/or mortality in patients with severe SARS-CoV-2 pneumonia.

Authors+Show Affiliations

Infectious Disease Department, Nord Franche-Comté Hospital, 90400 Trévenans, France. Electronic address: timothee.klopfenstein@hnfc.fr.Infectious Disease Department, Nord Franche-Comté Hospital, 90400 Trévenans, France. Electronic address: souhail.zayet@gmail.com.Rheumatology Department, Nord Franche-Comté Hospital, 90400 Trévenans, France.Rheumatology Department, Nord Franche-Comté Hospital, 90400 Trévenans, France.Intensive Care Unit Department, Nord Franche-Comté Hospital, 90400 Trévenans, France.Infectious Disease Department, Nord Franche-Comté Hospital, 90400 Trévenans, France.Infectious Disease Department, Nord Franche-Comté Hospital, 90400 Trévenans, France.Intensive Care Unit Department, Nord Franche-Comté Hospital, 90400 Trévenans, France.Infectious Disease Department, Nord Franche-Comté Hospital, 90400 Trévenans, France.Rheumatology Department, Nord Franche-Comté Hospital, 90400 Trévenans, France.Rheumatology Department, Nord Franche-Comté Hospital, 90400 Trévenans, France.Rheumatology Department, Nord Franche-Comté Hospital, 90400 Trévenans, France.Pharmacology Department, Nord Franche-Comté Hospital, 90400 Trévenans, France.Pharmacology Department, Nord Franche-Comté Hospital, 90400 Trévenans, France.Biological Department, Nord Franche-Comté Hospital, 90400 Trévenans, France.Biological Department, Nord Franche-Comté Hospital, 90400 Trévenans, France.Infectious Disease Department, Nord Franche-Comté Hospital, 90400 Trévenans, France.Rheumatology Department, Nord Franche-Comté Hospital, 90400 Trévenans, France.No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32387320

Citation

Klopfenstein, T, et al. "Tocilizumab Therapy Reduced Intensive Care Unit Admissions And/or Mortality in COVID-19 Patients." Medecine Et Maladies Infectieuses, vol. 50, no. 5, 2020, pp. 397-400.
Klopfenstein T, Zayet S, Lohse A, et al. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. Med Mal Infect. 2020;50(5):397-400.
Klopfenstein, T., Zayet, S., Lohse, A., Balblanc, J. C., Badie, J., Royer, P. Y., Toko, L., Mezher, C., Kadiane-Oussou, N. J., Bossert, M., Bozgan, A. M., Charpentier, A., Roux, M. F., Contreras, R., Mazurier, I., Dussert, P., Gendrin, V., & Conrozier, T. (2020). Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. Medecine Et Maladies Infectieuses, 50(5), 397-400. https://doi.org/10.1016/j.medmal.2020.05.001
Klopfenstein T, et al. Tocilizumab Therapy Reduced Intensive Care Unit Admissions And/or Mortality in COVID-19 Patients. Med Mal Infect. 2020;50(5):397-400. PubMed PMID: 32387320.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. AU - Klopfenstein,T, AU - Zayet,S, AU - Lohse,A, AU - Balblanc,J-C, AU - Badie,J, AU - Royer,P-Y, AU - Toko,L, AU - Mezher,C, AU - Kadiane-Oussou,N J, AU - Bossert,M, AU - Bozgan,A-M, AU - Charpentier,A, AU - Roux,M-F, AU - Contreras,R, AU - Mazurier,I, AU - Dussert,P, AU - Gendrin,V, AU - Conrozier,T, AU - ,, Y1 - 2020/05/06/ PY - 2020/04/29/received PY - 2020/05/04/accepted PY - 2020/5/11/pubmed PY - 2020/8/13/medline PY - 2020/5/11/entrez KW - COVID-19 KW - Intensive care unit KW - Mortality KW - SARS-CoV-2 KW - Tocilizumab SP - 397 EP - 400 JF - Medecine et maladies infectieuses JO - Med Mal Infect VL - 50 IS - 5 N2 - INTRODUCTION: No therapy has yet proven effective in COVID-19. Tocilizumab (TCZ) in patients with severe COVID-19 could be an effective treatment. METHOD: We conducted a retrospective case-control study in the Nord Franche-Comté Hospital, France. We compared the outcome of patients treated with TCZ and patients without TCZ considering a combined primary endpoint: death and/or ICU admissions. RESULTS: Patients with TCZ (n=20) had a higher Charlson comorbidity index (5.3 [±2.4] vs 3.4 [±2.6], P=0.014), presented with more severe forms (higher level of oxygen therapy at 13L/min vs 6L/min, P<0.001), and had poorer biological findings (severe lymphopenia: 676/mm3 vs 914/mm3, P=0.037 and higher CRP level: 158mg/L vs 105mg/L, P=0.017) than patients without TCZ (n=25). However, death and/or ICU admissions were higher in patients without TCZ than in the TCZ group (72% vs 25%, P=0.002). CONCLUSION: Despite the small sample size and retrospective nature of the work, this result strongly suggests that TCZ may reduce the number of ICU admissions and/or mortality in patients with severe SARS-CoV-2 pneumonia. SN - 1769-6690 UR - https://www.unboundmedicine.com/medline/citation/32387320/Tocilizumab_therapy_reduced_intensive_care_unit_admissions_and/or_mortality_in_COVID_19_patients_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0399-077X(20)30129-3 DB - PRIME DP - Unbound Medicine ER -